Your browser doesn't support javascript.
loading
Transversus abdominis plane block with liposomal bupivacaine for pain control after cesarean delivery: a retrospective chart review.
Baker, B Wycke; Villadiego, Lea G; Lake, Y Natasha; Amin, Yazan; Timmins, Audra E; Swaim, Laurie S; Ashton, David W.
Afiliação
  • Baker BW; Department of Obstetrical and Gynecological Anesthesiology, Texas Children's Hospital Pavilion for Women, Houston, TX, USA, bwbaker@texaschildrens.org.
  • Villadiego LG; US Anesthesia Partners, Houston, TX, USA, bwbaker@texaschildrens.org.
  • Lake YN; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA, bwbaker@texaschildrens.org.
  • Amin Y; Department of Anesthesiology, Baylor College of Medicine, Houston, TX, USA, bwbaker@texaschildrens.org.
  • Timmins AE; Department of Obstetrical and Gynecological Anesthesiology, Texas Children's Hospital Pavilion for Women, Houston, TX, USA, bwbaker@texaschildrens.org.
  • Swaim LS; US Anesthesia Partners, Houston, TX, USA, bwbaker@texaschildrens.org.
  • Ashton DW; Department of Obstetrical and Gynecological Anesthesiology, Texas Children's Hospital Pavilion for Women, Houston, TX, USA, bwbaker@texaschildrens.org.
J Pain Res ; 11: 3109-3116, 2018.
Article em En | MEDLINE | ID: mdl-30573987
BACKGROUND: Adverse effects of opioid analgesics and potential for chronic use are limitations in the cesarean setting. Regional anesthesia using transversus abdominis plane (TAP) block post-cesarean delivery may improve analgesia and reduce opioid consumption. Effectiveness of TAP block using liposomal bupivacaine (LB) to reduce post-cesarean pain is unknown. METHODS: We performed a single-center retrospective chart review of patients aged ≥18 years who underwent cesarean delivery with a multimodal pain management protocol with or without TAP block with LB 266 mg. Assessments included postsurgical opioid consumption; area under the curve (AUC) of numeric rating scale pain scores from 0 to 3 days; proportion of opioid-free patients; discharge- and post-anesthesia care unit (PACU)-ready time; times to ambulation, solid food, and bowel movement; hospital length of stay (LOS); and adverse events (AEs). Data were analyzed in the total population and in first- and repeat-cesarean subgroups using Wilcoxon, chi-squared, and Student's t-tests. RESULTS: Of 201 patients, 101 were treated with LB TAP block (LB-TAPB) and 100 without LB-TAPB. Treatment with LB-TAPB vs without LB-TAPB significantly reduced mean post-surgical opioid consumption (total, 47%; first-cesarean, 54%; repeat-cesarean, 42%; P<0.001 each) and mean AUC of pain scores (total, 46%; first-cesarean, 57%; repeat-cesarean, 40%; P<0.001 each). Patients treated with LB-TAPB had significantly shorter mean discharge-ready times (2.9 vs 3.6 days; P=0.006), PACU-ready times (138 vs 163 minutes; P=0.028), and LOS (2.9 vs 3.9 days; P<0.001). LB-TAPB significantly decreased mean times to ambulation and solid food by 39% and 31% (P<0.01 each), respectively, and numerically reduced mean time to bowel movement (26%; P=0.05). Fewer patients treated with LB-TAPB vs without LB-TAPB reported an AE (34% vs 50%; P=0.026). CONCLUSION: These results suggest multimodal pain management incorporating TAP block with LB 266 mg is an effective approach to reducing opioid requirements and improving analgesia post-cesarean delivery.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: J Pain Res Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: J Pain Res Ano de publicação: 2018 Tipo de documento: Article